ST Pharm Co.Ltd (237690) - Cash Flow Conversion Efficiency

Latest as of December 2025: -0.036x

Based on the latest financial reports, ST Pharm Co.Ltd (237690) has a cash flow conversion efficiency ratio of -0.036x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-21.16 Billion ≈ $-14.34 Million USD) by net assets (₩593.00 Billion ≈ $401.87 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see how much is ST Pharm Co.Ltd worth for the company's overall valuation and market capitalisation.

ST Pharm Co.Ltd - Cash Flow Conversion Efficiency Trend (2015–2025)

This chart illustrates how ST Pharm Co.Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.

ST Pharm Co.Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of ST Pharm Co.Ltd ranked by their cash flow conversion efficiency. Explore ST Pharm Co.Ltd earnings quality ratio to measure how well operating cash flow supports reported net income.

Company Cash Flow Conversion Efficiency
Zimplats Holdings Ltd
AU:ZIM
0.089x
Ampoc Far-East Co Ltd
TW:2493
0.115x
Elan Microelectronics Corp
TW:2458
0.095x
Huizhou Speed Wireless Technology Co Ltd
SHE:300322
-0.085x
Fox-Wizel Ltd
TA:FOX
0.018x
Shanghai MicroPort EV MedTech Co. Ltd. A
SHG:688351
N/A
OVH GROUPE UNSP.ADR/1/2
F:7U70
N/A
Shenzhen Clou Electronics Co Ltd
SHE:002121
0.146x

Annual Cash Flow Conversion Efficiency for ST Pharm Co.Ltd (2015–2025)

The table below shows the annual cash flow conversion efficiency of ST Pharm Co.Ltd from 2015 to 2025. View current stock price of ST Pharm Co.Ltd for real-time trading data and today's change.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 ₩593.00 Billion
≈ $401.87 Million
₩13.99 Billion
≈ $9.48 Million
0.024x -89.16%
2024-12-31 ₩502.99 Billion
≈ $340.87 Million
₩109.45 Billion
≈ $74.17 Million
0.218x +6384.31%
2023-12-31 ₩386.91 Billion
≈ $262.20 Million
₩1.30 Billion
≈ $879.90K
0.003x -83.89%
2022-12-31 ₩337.63 Billion
≈ $228.81 Million
₩7.03 Billion
≈ $4.76 Million
0.021x -7.48%
2021-12-31 ₩322.97 Billion
≈ $218.87 Million
₩7.27 Billion
≈ $4.93 Million
0.023x +131.75%
2020-12-31 ₩295.33 Billion
≈ $200.14 Million
₩-20.93 Billion
≈ $-14.19 Million
-0.071x +30.09%
2019-12-31 ₩300.96 Billion
≈ $203.95 Million
₩-30.52 Billion
≈ $-20.68 Million
-0.101x -412.25%
2018-12-31 ₩331.57 Billion
≈ $224.70 Million
₩10.77 Billion
≈ $7.30 Million
0.032x -79.06%
2017-12-31 ₩351.08 Billion
≈ $237.92 Million
₩54.44 Billion
≈ $36.89 Million
0.155x -4.35%
2016-12-31 ₩313.24 Billion
≈ $212.28 Million
₩50.78 Billion
≈ $34.41 Million
0.162x -42.38%
2015-12-31 ₩127.33 Billion
≈ $86.29 Million
₩35.82 Billion
≈ $24.28 Million
0.281x --

About ST Pharm Co.Ltd

KQ:237690 Korea Pharmaceuticals
Market Cap
$1.16 Billion
₩1.71 Trillion KRW
Market Cap Rank
#8267 Global
#214 in Korea
Share Price
₩91900.00
Change (1 day)
+1.66%
52-Week Range
₩84700.00 - ₩168700.00
All Time High
₩168700.00
About

ST Pharm Co. Ltd., a contract development manufacturing organization, provides products for pharmaceutical and non-pharmaceutical area in South Korea. The company offers chemistry manufacturing control (CMC) services, which includes analytical method development; in-house reference standard testing; analytical method qualification/validation; analytical characterization; and CMC documentation. It… Read more